Ex-CytoDyn CEO sentenced to 30 months for pump-and-dump schemenews2026-01-26T18:32:33+00:00January 26th, 2026|Endpoints News|
Catalent plans to close Belgium cell therapy sitenews2026-01-26T17:45:49+00:00January 26th, 2026|Endpoints News|
Sarepta touts three-year Duchenne gene therapy data after patient deathsnews2026-01-26T16:17:47+00:00January 26th, 2026|Endpoints News|
Genyro licences DNA builder from Caltech; Dizal targets Hong Kong listingnews2026-01-26T15:07:04+00:00January 26th, 2026|Endpoints News|
UK medicines agency seized 20M illegal drugs last year, including GLP-1snews2026-01-26T12:13:59+00:00January 26th, 2026|Endpoints News|
Genmab halts enrollment for cancer drug from ProfoundBio buyoutnews2026-01-26T11:31:04+00:00January 26th, 2026|Endpoints News|
First-movers respond to herding; BioMarin vets start new biotech; GSK buys RAPT Therapeutics; and morenews2026-01-24T11:00:43+00:00January 24th, 2026|Endpoints News|
Novo’s Wegovy pill off to a solid start after just two weeks on marketnews2026-01-23T20:23:41+00:00January 23rd, 2026|Endpoints News|
EU kicks off one-year pilot to expedite multinational trialsnews2026-01-23T19:24:15+00:00January 23rd, 2026|Endpoints News|
ACIP members depict diverging goals after schedule changenews2026-01-23T18:24:41+00:00January 23rd, 2026|Endpoints News|
